The aim of the present analysis was to evaluate the efficacy of the glucagon-like peptide-1 receptor agonist liraglutide in Latino/Hispanic individuals with type 2 diabetes, in addition to comparing its treatment effects with those observed in non-Latino/Hispanic individuals. Analyses were performed on patient-level data from a subset of individuals self-defined as Latino/Hispanic from four phase III studies, the LEAD-3, LEAD-4, LEAD-6 and 1860-LIRA-DPP-4 trials. Endpoints included change in glycated haemoglobin (HbA1c) and body weight from baseline. In Latino/Hispanic patients (n = 505; 323 treated with liraglutide) after 26 weeks, mean HbA1c reductions were significantly greater with both liraglutide 1.2 and 1.8 mg versus comparator or placebo in the LEAD-3 and LEAD-4 studies, and with 1.8 mg liraglutide in the 1860-LIRA-DPP-4 trial. In LEAD-3 both doses led to significant differences in body weight change among Latino/Hispanic patients versus the comparator. With 1.8 mg liraglutide, difference in weight change was significant only in the 1860-LIRA-DPP-4 trial versus sitagliptin. For both endpoints Latino/Hispanic and non-Latino/Hispanic patients responded to liraglutide similarly. In summary, liraglutide is efficacious for treatment of type 2 diabetes in Latino/Hispanic patients, with a similar efficacy to that seen in non-Latino/Hispanic patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dom.12653 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real World Data in Stage III Melanoma in Latino Low Middle Income Country: Prognostic Factors and Outcomes.
J Surg Oncol
December 2024
Department of Breast and Soft Tissue Tumors Surgery, Instituto Nacional de Enfermedades Neoplasticas (INEN), Lima, Peru.
Introduction: Malignant melanoma is a heterogeneous disease, with varying outcomes depending on the patient's race and ethnicity. Advanced stages can be tackled by novel targeted therapies and immunotherapy. We aimed to investigate the real-world data in Latino-Hispanic patients diagnosed with Stage III melanoma residing in Peru, a region marked by limited resources and healthcare infrastructure.
View Article and Find Full Text PDFCompliance With Routine Health Checkup Visits Among California-Based Minority Men: A Survey Study.
Am J Mens Health
January 2025
MiOra-Public Health Non-profit Organization, Encino, CA, USA.
Article Synopsis
- The study examines health care disparities among minority men in California, particularly post-pandemic impacts on routine health checkup compliance.
- A survey of 266 male respondents revealed that despite high insurance coverage, only 50.8% attended routine checkups, highlighting issues related to accessibility and health insurance literacy.
- Key factors affecting compliance included demographics such as zip code and the ability to find insurance-covered clinics, indicating significant barriers that need to be addressed to improve health outcomes in this population.
Improving representation of Hispanic adults in a population-based cancer genetics cohort: Qualitative findings from the Healthy Oregon Project.
J Clin Transl Sci
May 2024
Oregon Health & Science University, Portland, OR, USA.
Background: Members of many racial and ethnic population subgroups are underrepresented in clinical trials and research. We present perspectives on barriers and facilitators to study participation gathered from Hispanic participants in a population-based genetic screening study.
Methods: Seven focus groups (five in English and two in Spanish) were conducted with self-identified Hispanic participants of the Healthy Oregon Project (HOP), a large population-based cohort of adults residing in Oregon.
Racial and Ethnic Disparities in Prescribing of GLP-1 Receptor Agonists in the United States: A Retrospective Cohort Analysis.
medRxiv
November 2024
Department of Pharmacotherapy, University of Utah, Salt Lake City, UT, United States.
Article Synopsis
- Type 2 diabetes (T2D) is a significant health issue in the U.S., and this study focuses on how racial and ethnic differences affect the prescription of effective diabetes medications.
- The research analyzed data from 57,320 patients, revealing notable disparities in the prescription rates of GLP-1 medications like tirzepatide, semaglutide, and dulaglutide among different racial and ethnic groups compared to White patients.
- The findings suggest that these disparities could lead to worse health outcomes for underrepresented groups, signaling a need for targeted interventions to ensure equitable access to diabetes care.
WMH Contributions to Cognitive Impairment: Rationale and Design of the Diverse VCID Study.
Stroke
November 2024
Brown Foundation Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston (M.F.).
As awareness of dementia increases, more individuals with minor cognitive complaints are requesting clinical assessment. Neuroimaging studies frequently identify incidental white matter hyperintensities, raising patient concerns about their brain health and future risk for dementia. Moreover, current US demographics indicate that ≈50% of these individuals will be from diverse backgrounds by 2060.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!